Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Depotech(depo) -- Ignore unavailable to you. Want to Upgrade?

To: Czechsinthemail who wrote (554)	12/18/1997 7:25:00 PM
From: Cymeed	Read Replies (2) \| Respond to of 887

What kind of efficacy improvement is FDA normally looking for ? DepoCyte = 8/31 = 25.8% Compare = 6/30 = 20% Is this not enough to justify a better efficacy ? On side effects: All cancer drugs have side effects. Does Depocyte cause more ? Why ? I thought the less dosage cause less side effect. Less side effect was thought to be a winning card for Depo, how come it turned to be against Depo ? Is FDA lost in the bureacratic statistical maniac, without seeing common sense (less dosage would cause less side effects) ? BTW, where is everybody ? Did the crowd die with DepoCyte ? We still got a lot to talk about ! Disappointed, yes; Financial damaged, you bet; But we still need to find out a way to handle those losing Depo shares - hopefully the best way. What options does the company at this time ?